Cingulate (CING) Competitors $5.50 +0.13 (+2.42%) Closing price 04:00 PM EasternExtended Trading$5.60 +0.09 (+1.73%) As of 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CING vs. CNTB, OTLK, VRCA, ADAP, MIST, SRZN, PYXS, ANRO, JMAC, and BMEAShould you be buying Cingulate stock or one of its competitors? The main competitors of Cingulate include Connect Biopharma (CNTB), Oncobiologics (OTLK), Verrica Pharmaceuticals (VRCA), Adaptimmune Therapeutics (ADAP), Milestone Pharmaceuticals (MIST), Surrozen (SRZN), Pyxis Oncology (PYXS), Alto Neuroscience (ANRO), Maxpro Capital Acquisition (JMAC), and Biomea Fusion (BMEA). These companies are all part of the "pharmaceutical products" industry. Cingulate vs. Its Competitors Connect Biopharma Oncobiologics Verrica Pharmaceuticals Adaptimmune Therapeutics Milestone Pharmaceuticals Surrozen Pyxis Oncology Alto Neuroscience Maxpro Capital Acquisition Biomea Fusion Cingulate (NASDAQ:CING) and Connect Biopharma (NASDAQ:CNTB) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, valuation, analyst recommendations, profitability, earnings and risk. Which has preferable earnings & valuation, CING or CNTB? Cingulate has higher earnings, but lower revenue than Connect Biopharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCingulateN/AN/A-$15.55M-$8.48-0.65Connect Biopharma$26.03M4.74-$15.63MN/AN/A Does the media refer more to CING or CNTB? In the previous week, Connect Biopharma had 9 more articles in the media than Cingulate. MarketBeat recorded 11 mentions for Connect Biopharma and 2 mentions for Cingulate. Cingulate's average media sentiment score of 1.87 beat Connect Biopharma's score of 0.68 indicating that Cingulate is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cingulate 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Connect Biopharma 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend CING or CNTB? Cingulate currently has a consensus price target of $26.00, indicating a potential upside of 372.73%. Connect Biopharma has a consensus price target of $7.00, indicating a potential upside of 215.32%. Given Cingulate's higher possible upside, equities analysts plainly believe Cingulate is more favorable than Connect Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cingulate 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Connect Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Is CING or CNTB more profitable? Connect Biopharma's return on equity of 0.00% beat Cingulate's return on equity.Company Net Margins Return on Equity Return on Assets CingulateN/A -229.78% -142.28% Connect Biopharma N/A N/A N/A Do insiders and institutionals have more ownership in CING or CNTB? 41.3% of Cingulate shares are held by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are held by institutional investors. 5.3% of Cingulate shares are held by insiders. Comparatively, 22.6% of Connect Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has more volatility & risk, CING or CNTB? Cingulate has a beta of -0.79, suggesting that its share price is 179% less volatile than the S&P 500. Comparatively, Connect Biopharma has a beta of -0.2, suggesting that its share price is 120% less volatile than the S&P 500. SummaryConnect Biopharma beats Cingulate on 9 of the 13 factors compared between the two stocks. Get Cingulate News Delivered to You Automatically Sign up to receive the latest news and ratings for CING and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CING and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CING vs. The Competition Export to ExcelMetricCingulateMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$28.33M$3.04B$5.74B$9.51BDividend YieldN/A2.40%4.60%3.99%P/E Ratio-0.6521.1828.1120.03Price / SalesN/A339.43461.37103.88Price / CashN/A43.2336.5559.01Price / Book2.378.368.655.90Net Income-$15.55M-$55.19M$3.25B$258.66M7 Day Performance6.38%5.89%4.20%2.23%1 Month Performance33.82%17.63%10.82%12.76%1 Year Performance1,347.37%5.09%34.70%19.36% Cingulate Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CINGCingulate3.2576 of 5 stars$5.50+2.4%$26.00+372.7%+1,352.1%$28.33MN/A-0.6520News CoveragePositive NewsCNTBConnect Biopharma2.8479 of 5 stars$1.41-7.2%$7.00+396.5%+74.1%$78.34M$26.03M0.00110Analyst UpgradeAnalyst RevisionHigh Trading VolumeOTLKOncobiologics2.258 of 5 stars$2.32+12.1%$9.60+313.8%-75.5%$77.88MN/A-2.5520News CoverageVRCAVerrica Pharmaceuticals4.1329 of 5 stars$0.82+1.0%$8.00+881.6%-90.2%$75.38M$7.57M-0.6840Positive NewsGap DownADAPAdaptimmune Therapeutics1.9629 of 5 stars$0.28+4.6%$1.35+381.0%-73.0%$74.48M$178.03M-1.04490News CoverageMISTMilestone Pharmaceuticals2.8103 of 5 stars$1.38-11.5%$7.00+407.2%+6.1%$73.78M$1M-1.7730High Trading VolumeSRZNSurrozen2.7641 of 5 stars$8.61-1.1%$38.50+347.2%+5.3%$73.73M$11.64M-0.3480Positive NewsPYXSPyxis Oncology2.4157 of 5 stars$1.19+2.6%$9.00+656.3%-64.5%$73.72MN/A-0.7560ANROAlto Neuroscience2.4036 of 5 stars$2.71+4.0%$8.50+214.2%-79.4%$73.22MN/A-1.16N/ATrending NewsJMACMaxpro Capital AcquisitionN/A$5.45-4.4%N/A+2,812.2%$73.18MN/A0.002,021Gap UpBMEABiomea Fusion3.2899 of 5 stars$1.94-3.0%$21.40+1,003.1%-66.8%$72.89MN/A-0.5550Upcoming Earnings Related Companies and Tools Related Companies Connect Biopharma Competitors Oncobiologics Competitors Verrica Pharmaceuticals Competitors Adaptimmune Therapeutics Competitors Milestone Pharmaceuticals Competitors Surrozen Competitors Pyxis Oncology Competitors Alto Neuroscience Competitors Maxpro Capital Acquisition Competitors Biomea Fusion Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CING) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cingulate Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cingulate With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
